Finding functions for unknown GPCRs is hard but key for making new drugs.
May 2025 in “Experimental Dermatology” Triphenylphosphine oxide can increase oil production and reduce inflammation in skin cells without affecting TRPM5.
April 1992 in “Current opinion in therapeutic patents” New steroids were patented as effective for treating acne, hair loss, and other conditions related to hormones.
25 citations
,
March 2004 in “Regulatory Toxicology and Pharmacology” Using testosterone-stimulated weanling rats can effectively replace castrated rats for anti-androgen testing, reducing animal stress.
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
4 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” 7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
28 citations
,
January 2010 in “Biological & pharmaceutical bulletin” Certain essential oils can activate a human skin receptor, potentially helping with skin disorders.
A new compound from Royoporus badius activates immune cells and induces inflammatory responses.
1 citations
,
January 2014 in “PubMed” Certain substances can decrease or increase exploratory behavior in rodents.
30 citations
,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
October 2016 in “Letters in Drug Design & Discovery” August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
March 2026 in “Food Science & Nutrition” Arachis hypogaea L. root extract reduces prostate enlargement and inflammation in mice.
64 citations
,
March 2008 in “Neuropsychopharmacology”
16 citations
,
September 2016 in “Neuropharmacology” Activating TSPO helps protect the retina from damage caused by high eye pressure in glaucoma.
6 citations
,
August 2004 in “Journal of Chemical Information and Computer Sciences” The research found a link between certain molecular features and the biological activity of BC3, which can help identify or create new active compounds.
1 citations
,
September 2024 in “Frontiers in Pharmacology” Aumolertinib effectively controls lung cancer and improves quality of life.
15 citations
,
May 1987 in “Fundamental and applied toxicology” SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe side effects.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
January 1993 in “Claves de razón práctica” ROR2 is crucial for hair follicle stem cell maintenance and self-renewal.
June 2026 in “Open Access Research Journal of Biology and Pharmacy” Bedaquiline, Telmisartan, Diosmin, Azelastine, and Adapalene may be effective treatments for onchocerciasis.
18 citations
,
January 2001 in “Annual Reports in Medicinal Chemistry” Selective Androgen Receptor Modulators (SARMs) are drugs that can control the effects of androgens in different tissues, potentially having fewer side effects and promising for treating various conditions.
34 citations
,
August 2015 in “Frontiers in Behavioral Neuroscience” Allopregnanolone affects fear responses differently in male and female rats, possibly explaining sex differences in anxiety disorders.
Suppressing ODC activity reduces tumor growth in hair follicles.